Bioenergetic analysis of ovarian cancer cell lines: Profiling of histological subtypes and identification of a mitochondria-defective cell line

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Dier, Usawadee ^a   Shin, Dong Hui ^a   Madhubhani, L P ^a   Hemachandra, P ^a   Uusitalo, Larissa M ^a   Hempel, Nadine ^a  

^a SUNY POLYTECHNIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; MITOCHONDRIAL PROTEIN; PROTEIN DRP1; ROTENONE; UNCLASSIFIED DRUG; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTON IONOPHORE; TUMOR PROTEIN;

ACIDIFICATION; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BIOENERGY; CANCER CLASSIFICATION; CANCER INHIBITION; CELL HYPOXIA; CHEMOSENSITIVITY; DIFFERENTIAL DIAGNOSIS; ES 2 CELL LINE; EXTRACELLULAR ACIDIFICATION RATE; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLIC FLUX ANALYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OVARIAN CANCER CELL LINE; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; OVCA420 CELL LINE; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; TOV 21 G CELL LINE; TUMOR SPHEROID; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL DYNAMICS; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OXYGEN CONSUMPTION; PROTON IONOPHORES;

EID: 84901440552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098479     Document Type: Article

References (59)

1. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, et al. (2013) New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int 2013: 852839.
2. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11: 719-725.
3. Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42: 918-931.
4. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56.
5. Tan DS, Miller RE, Kaye SB (2013) New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer 108: 1553-1559.
6. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, et al. (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17: 1521-1534.
7. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
8. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
9. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC (2006) PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101: 71-75.
10. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, et al. (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601.
11. Munksgaard PS, Blaakaer J (2012) The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 124: 164-169.
12. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, et al. (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752.
13. Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, et al. (2011) Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 310: 129-133.
14. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, et al. (2011) Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 71: 5081-5089.
15. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, et al. (2011) Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6: e21121.
16. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, et al. (2008) Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 14: 32-40. (Pubitemid 351377975)
17. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, et al. (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337. (Pubitemid 12235035)
18. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr, et al. (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83: 921-926. (Pubitemid 19080625)
19. Hill BG, Benavides GA, Lancaster JR Jr, Ballinger S, Dell'Italia L, et al. (2012) Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol Chem 393: 1485-1512.
20. Dranka BP, Hill BG, Darley-Usmar VM (2010) Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. Free Radic Biol Med 48: 905-914.
21. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, et al. (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512. (Pubitemid 37466491)
22. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811. (Pubitemid 351793778)
23. Pejznochova M, Tesarova M, Honzik T, Hansikova H, Magner M, et al. (2008) The developmental changes in mitochondrial DNA content per cell in human cord blood leukocytes during gestation. Physiol Res 57: 947-955.
24. Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, et al. (2013) Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines. PLoS One 8: e59180.
25. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, et al. (2000) Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res 60: 5349-5353.
26. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, et al. (2002) Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 532: 256-260. (Pubitemid 35375900)
27. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, et al. (2003) Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 64: 51-58. (Pubitemid 36759817)
28. Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, et al. (2013) Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog.
29. Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35: 427-433.
30. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY (2006) Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer 95: 1087-1091. (Pubitemid 44606837)
31. Labrousse AM, Zappaterra MD, Rube DA, van der Bliek AM (1999) C. elegans dynamin-related protein DRP-1 controls severing of the mitochondrial outer membrane. Mol Cell 4: 815-826.
32. Smirnova E, Griparic L, Shurland DL, van der Bliek AM (2001) Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 12: 2245-2256. (Pubitemid 33051954)
33. Uo T, Dworzak J, Kinoshita C, Inman DM, Kinoshita Y, et al. (2009) Drp1 levels constitutively regulate mitochondrial dynamics and cell survival in cortical neurons. Exp Neurol 218: 274-285.
34. Strack S, Wilson TJ, Cribbs JT (2013) Cyclin-dependent kinases regulate splice-specific targeting of dynamin-related protein 1 to microtubules. J Cell Biol 201: 1037-1051.
35. Cuff J, Salari K, Clarke N, Esheba GE, Forster AD, et al. (2013) Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS One 8: e74562.
36. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, et al. (2006) Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26: 3561-3566. (Pubitemid 44701539)
37. Anderson AS, Roberts PC, Frisard MI, McMillan RP, Brown TJ, et al. (2013) Metabolic changes during ovarian cancer progression as targets for sphingosine treatment. Exp Cell Res 319: 1431-1442.
38. Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, et al. (2010) Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol 202: 371 e371-378.
39. Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ (2013) Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol.
40. Kueck A, Opipari AW Jr, Griffith KA, Tan L, Choi M, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 107: 450-457. (Pubitemid 350160855)
41. Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W, Pratoomsoot C, Saokeaw S, et al. (2013) The effects of metformin on ovarian cancer: a systematic review. Int J Gynecol Cancer 23: 1544-1551.
42. Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, et al. (2009) CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer 115: 1395-1403.
43. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, et al. (2012) Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 19: 1966-1972.
44. Yamamoto Y, Oguri H, Yamada R, Maeda N, Kohsaki S, et al. (2008) Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet 102: 124-127.
45. Thrall MM, DeLoia JA, Gallion H, Avril N (2007) Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105: 17-22. (Pubitemid 46441448)
46. Rattan R, Giri S, Hartmann LC, Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178.
47. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126.
48. Fabian C, Koetz L, Favaro E, Indraccolo S, Mueller-Klieser W, et al. (2012) Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS J 279: 882-891.
49. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, et al. (1998) Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 95: 11715-11720. (Pubitemid 28460480)
50. Chandel NS (2010) Mitochondrial regulation of oxygen sensing. Adv Exp Med Biol 661: 339-354.
51. Hamanaka RB, Chandel NS (2009) Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr Opin Cell Biol 21: 894-899.
52. Dehne N, Brune B (2012) Sensors, Transmitters, and Targets in Mitochondrial Oxygen Shortage-A Hypoxia-Inducible Factor Relay Story. Antioxid Redox Signal.
53. Taylor CT (2008) Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 409: 19-26.
54. Montessuit S, Somasekharan SP, Terrones O, Lucken-Ardjomande S, Herzig S, et al. (2010) Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. Cell 142: 889-901.
55. Qian W, Wang J, Van Houten B (2013) The role of dynamin-related protein 1 in cancer growth: a promising therapeutic target? Expert Opin Ther Targets 17: 997-1001.
56. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, et al. (2012) Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J 26: 2175-2186.
57. Hagenbuchner J, Kuznetsov AV, Obexer P, Ausserlechner MJ (2013) BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 32: 4748-4757.
58. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
59. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.